Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tyson Foods, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Tyson Foods, Inc. trades at $58.01 (market cap $20.36B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.53% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TSN | |
|---|---|---|
Market Cap | $39.89B | $20.36B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $68.75 |
52-Week Low | $278.09 | $50.72 |
Enterprise Value | $38.15B | $27.95B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Tyson Foods (TSN) trades at $57.83, showing modest daily gains. The stock presents mixed signals with a bearish technical outlook but strong analyst support (50% buy ratings) and a consensus price target of $69.75. Recent earnings have beaten expectations in two of the last three quarters, while fundamentals show stable revenue near $54.4 billion but thin net margins of 0.81%. The company maintains dividend payments and is focusing on prepared foods growth.
The investment case balances value metrics like low P/S of 0.37 against profitability challenges. Upside potential exists if margin improvements materialize, but risks include volatile input costs and competitive pressures. The stock appears undervalued relative to analyst targets, suggesting cautious optimism for patient investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
